Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 178 matching drugs for PRKCZ — including drugs targeting any of its 41 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
midostaurin PRKCZ Direct yes 0
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis PDPK1 SSL via PDPK1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib EPHB4 SSL via EPHB4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 SSL via ERBB2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR3 SSL via FGFR3 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MST1R SSL via MST1R 3
afatinib ERBB2 SSL via ERBB2 yes 3
crizotinib MST1R SSL via MST1R 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR3 SSL via FGFR3 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB2 SSL via ERBB2 3
pembrolizumab, belzutifan, lenvatinib FGFR3 SSL via FGFR3 3
trastuzumab emtansine ERBB2 SSL via ERBB2 yes 3
tucatinib ERBB2 SSL via ERBB2 yes 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB2 SSL via ERBB2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR3 SSL via FGFR3 2
bbi-355, erlotinib, futibatinib FGFR3 SSL via FGFR3 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment EPHB4 SSL via EPHB4 2
bryostatin 1, paclitaxel PRKCA SSL via PRKCA 2
bryostatin 1, paclitaxel PRKCE SSL via PRKCE 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy PDPK1 SSL via PDPK1 2
cpt- 11, cisplatin, celecoxib, radiation, surgery PDPK1 SSL via PDPK1 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ERBB2 SSL via ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ERBB2 SSL via ERBB2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR3 SSL via FGFR3 2
lapatinib ERBB2 SSL via ERBB2 yes 2
lenvatinib, pembrolizumab FGFR3 SSL via FGFR3 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FGFR3 SSL via FGFR3 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FGFR3 SSL via FGFR3 2
nintedanib FGFR3 SSL via FGFR3 yes 2
nintedanib, pembrolizumab FGFR3 SSL via FGFR3 2
pazopanib FGFR3 SSL via FGFR3 yes 2
pembrolizumab, lenvatinib FGFR3 SSL via FGFR3 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FGFR3 SSL via FGFR3 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FGFR3 SSL via FGFR3 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FGFR3 SSL via FGFR3 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies ERBB2 SSL via ERBB2 2
trastuzumab ERBB2 SSL via ERBB2 yes 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy ERBB2 SSL via ERBB2 2
trastuzumab, tipifarnib ERBB2 SSL via ERBB2 2
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks ERBB2 SSL via ERBB2 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy ERBB2 SSL via ERBB2 1
7-hydroxystaurosporine, fluorouracil PDPK1 SSL via PDPK1 1
7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis PDPK1 SSL via PDPK1 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB2 SSL via ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib EPHB4 SSL via EPHB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB2 SSL via ERBB2 1
afatinib, docetaxel, radiation therapy ERBB2 SSL via ERBB2 1
afatinib, gefitinib ERBB2 SSL via ERBB2 1
afatinib, irinotecan ERBB2 SSL via ERBB2 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab DNMT1 SSL via DNMT1 1
bevacizumab, dasatinib, placebo EPHB4 SSL via EPHB4 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging FGFR3 SSL via FGFR3 1
biopsy, biospecimen collection, crizotinib, radiologic examination MST1R SSL via MST1R 1
biopsy, biospecimen collection, echocardiography, pertuzumab, radiologic examination, trastuzumab ERBB2 SSL via ERBB2 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography FGFR3 SSL via FGFR3 1
botensilimab, balstilimab, chloroquine phosphate, celecoxib PDPK1 SSL via PDPK1 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab FGFR3 SSL via FGFR3 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab ERBB2 SSL via ERBB2 1
carboplatin, laboratory biomarker analysis, paclitaxel, quality-of-life assessment, radiation therapy, therapeutic conventional surgery, trastuzumab ERBB2 SSL via ERBB2 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
celecoxib, cyclophosphamide, etoposide, thalidomide PDPK1 SSL via PDPK1 1
celecoxib, isotretinoin, temozolomide, thalidomide PDPK1 SSL via PDPK1 1
celecoxib, temozolomide, thalidomide, adjuvant therapy PDPK1 SSL via PDPK1 1
cetuximab, trastuzumab ERBB2 SSL via ERBB2 1
cisplatin, 5-fluorouracil or capecitabine, trastuzumab, pertuzumab, gastrectomy ERBB2 SSL via ERBB2 1
cytoreductive surgery, perifosine, temsirolimus PRKCA SSL via PRKCA 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride EPHB4 SSL via EPHB4 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method EPHB4 SSL via EPHB4 1
dasatinib, laboratory biomarker analysis, physiologic testing EPHB4 SSL via EPHB4 1
dasatinib, mfolfox6 EPHB4 SSL via EPHB4 1
dasatinib, pharmacological study EPHB4 SSL via EPHB4 1
dasatinib, temozolomide, placebo, radiation therapy EPHB4 SSL via EPHB4 1
db-1310, trastuzumab, osimertinib ERBB2 SSL via ERBB2 1
decitabine, gemcitabine DNMT1 SSL via DNMT1 1
disitamab vedotin, tucatinib ERBB2 SSL via ERBB2 1
disulfiram, copper, alkylating agents ACY1 SSL via ACY1 1
disulfiram, copper, alkylating agents GPI SSL via GPI 1
docetaxel, leucovorin, fluorouracil, cisplatin, docetaxel, cisplatin, fluorouracil, neulasta, or neupogen, docetaxel, leukvorin, flurouracil, cisplatin, trastuzumab ERBB2 SSL via ERBB2 1
docetaxel, oxaliplatin, capecitabine, trastuzumab ERBB2 SSL via ERBB2 1
e. coli cd-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis DNMT1 SSL via DNMT1 1
erdafitinib FGFR3 SSL via FGFR3 yes 1
evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel ERBB2 SSL via ERBB2 1
flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, e. coli cd-expressing genetically modified neural stem cells DNMT1 SSL via DNMT1 1
fluorouracil (5-fu), capecitabine, durvalumab, oxaliplatin, trastuzumab, trastuzumab deruxtecan, cisplatin, pembrolizumab, volrustomig, rilvegostomig ERBB2 SSL via ERBB2 1
ft-2102, azacitidine, nivolumab, gemcitabine and cisplatin DNMT1 SSL via DNMT1 1
h101, tislelizumab, lenvatinib FGFR3 SSL via FGFR3 1
laboratory biomarker analysis, lapatinib, lapatinib ditosylate, pharmacological study, therapeutic conventional surgery ERBB2 SSL via ERBB2 1
laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery PRKCA SSL via PRKCA 1
lapatinib, chemoradiation, placebo ERBB2 SSL via ERBB2 1
lapatinib, placebo ERBB2 SSL via ERBB2 1
lapatinib, placebo, capecitabine, oxaliplatin ERBB2 SSL via ERBB2 1
lenvatinib, bevacizumab FGFR3 SSL via FGFR3 1
lonsurf, oxaliplatin, panitumumab, bevacizumab, trastuzumab, nivolumab ERBB2 SSL via ERBB2 1
nal-iri, oxaliplatin, 5-fu, trastuzumab, pembrolizumab, nivolumab ERBB2 SSL via ERBB2 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.